Arena Capital Advisors’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Arena Capital Advisors’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50,000	Closed	-$496K	–	347
2021 Q4	$496K	Hold	50,000	–	–	0.05%	198
2021 Q3	$495K	Buy	50,000 +1,587	+3%	+$15.6K	0.04%	213
2021 Q2	$475K	Buy	+48,413	New	+$472K	0.04%	284

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCMH

Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

Arena Capital Advisors's GRNA Position: Q1 2022 in Review

Arena Capital Advisors sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 50,000 shares — an estimated $496K sold.

Arena Capital Advisors first reported a position in GRNA in Q2 2021 and held it in 3 quarters. The position peaked at $496K in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

Arena Capital Advisors reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
Arena Capital Advisors sold 50,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $496K.
Arena Capital Advisors first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 3 quarters.
Arena Capital Advisors's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $496K in Q4 2021.
39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Arena Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.